Shield Therapeutics
plc
("Shield"
or the "Company" or the "Group")
Results of 2024 Annual
General Meeting
London, UK, 20 June 2024: Shield Therapeutics plc (LSE: STX), a commercial
stage pharmaceutical company that delivers Accrufer®/Feraccru®
(ferric maltol), an innovative and differentiated specialty
pharmaceutical product, to address a significant unmet need for
patients suffering from iron deficiency (with or without anaemia),
announces the voting results for each resolution
set out in the Notice of Annual General Meeting 2024. The Board
reports that all resolutions were passed: 1 to 10 passed as
ordinary resolutions and 11 to 12 passed as special
resolutions.
The following table shows the votes
cast on each resolution:
|
|
VOTES
FOR
|
%
|
VOTES AGAINST
|
%
|
WITHHELD VOTES
|
|
Resolution 1
|
371,135,672
|
99.65%
|
1,321,765
|
0.35%
|
387,002
|
|
Resolution 2
|
367,256,140
|
98.70%
|
4,821,667
|
1.30%
|
766,632
|
|
Resolution 3
|
368,781,407
|
99.11%
|
3,296,400
|
0.89%
|
766,632
|
|
Resolution 4
|
368,781,161
|
99.11%
|
3,296,646
|
0.89%
|
766,632
|
|
Resolution 5
|
369,852,377
|
99.40%
|
2,225,430
|
0.60%
|
766,632
|
|
Resolution 6
|
369,852,377
|
99.39%
|
2,266,765
|
0.61%
|
725,297
|
|
Resolution 7
|
368,193,486
|
98.96%
|
3,884,321
|
1.04%
|
766,632
|
|
Resolution 8
|
371,077,210
|
99.63%
|
1,380,227
|
0.37%
|
387,002
|
|
Resolution 9
|
370,260,710
|
99.38%
|
2,293,669
|
0.62%
|
290,060
|
|
Resolution 10
|
368,304,167
|
98.90%
|
4,079,150
|
1.10%
|
461,122
|
|
Resolution 11
|
368,067,995
|
98.84%
|
4,305,730
|
1.16%
|
470,714
|
|
Resolution 12
|
367,071,290
|
98.53%
|
5,470,921
|
1.47%
|
302,228
|
Notes:
1. Number of
shares in issue 782,056,367.
2. Details of the
votes received on the resolutions are available on the Company's
website:
https://www.shieldtherapeutics.com/corporate-documents/.
3. Shield
Therapeutics plc LEI: 213800G74QWY15FC3W71.
For further
information please contact:
|
Shield Therapeutics plc
|
www.shieldtherapeutics.com
|
|
Greg Madison, CEO
Santosh Shanbhag, CFO
|
+44 (0)
191 511 8500
|
|
Nominated Adviser and Joint Broker
|
|
|
Peel Hunt LLP
|
|
|
James Steel / Patrick
Birkholm
|
+44 (0)20
7418 8900
|
|
|
|
|
Joint Broker
Cavendish Ltd
Geoff Nash / George Dollemore/ Nigel
Birks /Harriet
Ward
|
+44 (0)20
7220 0500
|
|
|
|
|
Financial PR & IR Advisor
|
|
|
Walbrook PR
|
|
|
Charlotte Edgar / Alice
Woodings
|
+44 (0)20
7933 8780 or shield@walbrookpr.com
|
|
|
|
|
Investor Contact (US Advisor)
LifeSci Advisors, LLC
Joyce Allaire
|
jallaire@lifesciadvisors.com
|
About Iron Deficiency and
Accrufer®/Feraccru®
Clinically low iron levels (aka iron
deficiency, ID) can cause serious health problems for adults of all
ages, across multiple therapeutic areas. Together, ID and ID with
anaemia (IDA) affect about 20 million people in the U.S. and
represent a $2.3B market opportunity. As the first and only FDA
approved oral iron to treat ID/IDA, Accrufer® has the potential to
meet an important unmet medical need for both physicians and
patients.
Accrufer®/Feraccru® (ferric maltol)
is a novel, stable, non-salt-based oral therapy for adults with
ID/IDA. Accrufer®/Feraccru®
has a novel mechanism of absorption compared to
other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More
information about Accrufer®/Feraccru®, including the product
label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial-stage
specialty pharmaceutical company that delivers Accrufer®/Feraccru®
(ferric maltol), an innovative and differentiated pharmaceutical
product, to address a significant unmet need for patients suffering
from iron deficiency, with or without anaemia. The Company has launched Accrufer® in the U.S. with an
exclusive, multi-year commercial agreement with Viatris Inc.
(Viatris). Outside of the U.S., the Company has licensed the rights
to four specialty pharmaceutical companies. Feraccru® is
commercialised in the UK and European Union by Norgine B.V.
(Norgine), which also has marketing rights in Australia and New
Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and
commercialisation of Accrufer®/ Feraccru® in China, Hong Kong,
Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of
Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada.
To learn more about Shield Therapeutics, see our website at
www.shieldtherapeutics.com
or follow us on LinkedIn and X.
Accrufer®/Feraccru® has patent
coverage until the mid-2030s.
Accrufer®/Feraccru® are registered
trademarks of Shield Therapeutics.
